Martino R, Nomdedéu J, Altés A, Sureda A, Brunet S, Martínez C, Domingo-Albós A
Hematology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
Bone Marrow Transplant. 1994 Mar;13(3):265-9.
Patients with previous invasive fungal infections (IFI) are at high risk of reactivation of the infection during BMT, even after an apparently curative antifungal treatment. We report four patients who suffered an IFI after intensive chemotherapy for acute leukemia and were later submitted for BMT. One patient had developed a chronic systemic candidiasis during consolidation chemotherapy and received prophylactic oral or iv fluconazole (200 mg daily) throughout BMT. Two patients developed an invasive pulmonary aspergillosis after intensive chemotherapy, one of them after salvage therapy for post-allogeneic BMT relapse and the other after consolidation therapy. The former patient underwent partial lobectomy after treatment with amphotericin B before a second allogeneic BMT was performed. Both patients received prophylactic itraconazole (400 mg daily by mouth) throughout the BMT procedure. The fourth patient had pneumonia caused by Scedosporium apiospermum (the anamorph form of the fungus Pseudallescheria boydii) during consolidation chemotherapy which was successfully treated with itraconazole. During BMT he also received oral itraconazole (400 mg daily) as prophylaxis against reactivation of the infection. All four patients had successful BMT and none had clinical, radiological or microbiological evidence of reactivation of IFI during BMT.
既往有侵袭性真菌感染(IFI)的患者在骨髓移植(BMT)期间,即使经过明显有效的抗真菌治疗,仍有感染复发的高风险。我们报告了4例急性白血病强化化疗后发生IFI且随后接受BMT的患者。1例患者在巩固化疗期间发生慢性系统性念珠菌病,并在整个BMT过程中接受预防性口服或静脉注射氟康唑(每日200 mg)。2例患者在强化化疗后发生侵袭性肺曲霉病,其中1例在异基因BMT复发的挽救治疗后发生,另1例在巩固治疗后发生。前1例患者在接受两性霉素B治疗后行部分肺叶切除术,之后进行第二次异基因BMT。2例患者在整个BMT过程中均接受预防性伊曲康唑(每日口服400 mg)。第4例患者在巩固化疗期间发生由尖端赛多孢(真菌波氏假阿利什菌的无性型)引起的肺炎,经伊曲康唑成功治疗。在BMT期间,他也接受口服伊曲康唑(每日400 mg)以预防感染复发。所有4例患者BMT均成功,且在BMT期间均无IFI复发的临床、影像学或微生物学证据。